[go: up one dir, main page]

TW200510540A - Crystal structure - Google Patents

Crystal structure

Info

Publication number
TW200510540A
TW200510540A TW093112336A TW93112336A TW200510540A TW 200510540 A TW200510540 A TW 200510540A TW 093112336 A TW093112336 A TW 093112336A TW 93112336 A TW93112336 A TW 93112336A TW 200510540 A TW200510540 A TW 200510540A
Authority
TW
Taiwan
Prior art keywords
pde5
ligands
crystals
present
relates
Prior art date
Application number
TW093112336A
Other languages
Chinese (zh)
Inventor
David Graham Brown
Colin Roger Groom
Andrew Lee Hopkins
Timothy Mark Jenkins
Sarah Helen Kamp
Gara Margaret Mary O'
Heather Joan Ringrose
Colin Mark Robinson
Wendy Elaine Taylor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200510540A publication Critical patent/TW200510540A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to the soakable crystals of a phosphodiesterase 5 (PDE5) and their uses in identifying PDE5 ligands, including PDE5 ligands and inhibitor compounds. The present invention also relates to methods of identifying such PDE5 inhibitor compounds and their medical use. The present invention additionally relates to crystals of PDE5 into which ligands may be soaked and crystals of PDE5 comprising PDE5 ligands that have been soaked into the crystal.
TW093112336A 2003-05-01 2004-04-30 Crystal structure TW200510540A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0310058 2003-05-01

Publications (1)

Publication Number Publication Date
TW200510540A true TW200510540A (en) 2005-03-16

Family

ID=33397043

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093112336A TW200510540A (en) 2003-05-01 2004-04-30 Crystal structure

Country Status (10)

Country Link
EP (1) EP1623026A1 (en)
JP (1) JP2006525801A (en)
AR (1) AR044133A1 (en)
BR (1) BRPI0409931A (en)
CA (1) CA2522472A1 (en)
CL (1) CL2004000926A1 (en)
MX (1) MXPA05011769A (en)
RU (1) RU2005133628A (en)
TW (1) TW200510540A (en)
WO (1) WO2004097010A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137761A2 (en) * 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698716A1 (en) * 1993-05-27 1994-12-08 The Board Of Regents Of The University Of Washington Cyclic gmp-binding, cyclic gmp-specific phosphodiesterase materials and methods
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
GB0126417D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Crystal structure

Also Published As

Publication number Publication date
EP1623026A1 (en) 2006-02-08
RU2005133628A (en) 2007-05-10
CA2522472A1 (en) 2004-11-11
JP2006525801A (en) 2006-11-16
AR044133A1 (en) 2005-08-24
WO2004097010A1 (en) 2004-11-11
MXPA05011769A (en) 2006-01-26
BRPI0409931A (en) 2006-04-25
CL2004000926A1 (en) 2005-04-22

Similar Documents

Publication Publication Date Title
DE60210093D1 (en) BETA-AMINO-TETRAHYDROIMIDAZO (1,2-A) PYRAZINE AND -ETRAHYDROTRIAZOLO (4,3-A) PYRAZINE AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
AP2004003161A0 (en) Substituted benzazoles and use thereof as raf kinase inhibitors.
ZA200701137B (en) Triazolophthalazines
IL176020A0 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
MX2010006378A (en) Gamma secretase modulators.
EE200300227A (en) Methods for the Treatment of P38 Kinase Related Conditions and Pyrrolotriazine Compounds Useful as Kinase Inhibitors
UA93351C2 (en) Phthalazine derivatives as parp inhibitors
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2004103959A3 (en) Heterocyclic compounds and uses thereof
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
MXPA05012880A (en) Complement inhibitors from ticks.
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
PL373841A1 (en) Biphasic composition induced by polydextrose
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
CA2533963A1 (en) Urea derivatives and the use thereof as inhibitors of tyrosine kinases
WO2005009928A3 (en) Preparation and use of alkylating agents
MY142252A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
MXPA05009014A (en) Ccr-3 receptor antagonists.
WO2004087066A3 (en) Hif-1 inhibitors
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
WO2007120333A3 (en) Tetracyclic kinase inhibitors
UA83203C2 (en) Thiazol-(bi)cycloalkyl-carboxanilides and their use for fighting against undesirable microorganisms
YU36104A (en) Crystal structure of phosphodiesterase 5 and use thereof
AP1963A (en) Substituted pyrrole derivatives and their use as HMG-co inhibitors